CD8 BINDING AGENTS AND USE THEREOF Russian patent published in 2024 - IPC C07K16/28 A61K39/395 A61K51/10 G01N33/53 

FIELD: biotechnology.

SUBSTANCE: invention relates to biotechnology, namely to an agent binding to CD8, a method for production thereof, as well as to a labelled agent, a composition and a kit containing it. Also disclosed is an isolated nucleic acid encoding said agent, as well as a vector and a cell containing said nucleic acid.

EFFECT: invention is effective for detecting CD8+ cells in a subject, for predicting sensitivity of a subject with cancer to an immunotherapeutic agent, a cell therapy or an anti-cancer vaccine, for monitoring the progression of a disease in a subject with cancer, for monitoring the progress of treatment in a subject with cancer having received or receiving an immunotherapeutic agent, cell therapy or cancer vaccine, for predicting the susceptibility of a subject with an autoimmune disease or condition, graft-versus-host disease to an immunotherapeutic agent, for monitoring disease progression in a subject with an autoimmune disease or condition, graft rejection or graft versus host disease, for monitoring the progress of treatment in a subject with an autoimmune disease or condition, graft rejection or graft versus host disease having received or receiving an immunotherapeutic agent, as well as for identifying intestinal microbial strains associated with subjects sensitive to treatment with an immunotherapeutic agent.

82 cl, 11 dwg, 6 tbl, 4 ex